Beijing Chest Hospital
首都医科大学附属北京胸科医院
Listed for 3 of the 61 diseases this site covers, from the research papers it led and the trials registered with it as lead sponsor or site.
Research activity in public records, not a rating of care. Whether the hospital can help a particular patient is for the hospital and the treating doctor to say.
No official website checked for this hospital yet.
Research at Beijing Chest Hospital
Choose a disease to see the papers and trials behind it. Each tile shows papers led, 2021–2025, and papers per year.
Only the 61 diseases this site covers. A disease it is not listed for means this hospital did not meet the listing rule for that disease in these records; it does not mean the hospital does not treat it. Which hospitals are listed
- Lung cancer肺癌80 papers led2 open trials led
- Neuroblastoma神经母细胞瘤1 paper led
- Idiopathic pulmonary fibrosis特发性肺纤维化0 papers led
Not listed for: Nasopharyngeal carcinoma, Oesophageal squamous cell carcinoma, Hepatocellular carcinoma, Stomach cancer, Pancreatic cancer, Breast cancer, Glioma, Hepatoblastoma, Retinoblastoma, Chordoma, Osteosarcoma, Gastrointestinal stromal tumour, Ewing sarcoma, Multiple myeloma, B-cell acute lymphoblastic leukaemia, Aplastic anaemia, Haemophagocytic lymphohistiocytosis, Lymphoma, Beta thalassaemia, Haemophilia A, Atypical haemolytic uraemic syndrome, Thrombotic thrombocytopenic purpura, Fanconi anaemia, Neuromyelitis optica spectrum disorder, IgG4-related disease, Myasthenia gravis, Moyamoya disease, Wilson disease, Biliary atresia, Coronary heart disease, Congenital heart disease, Scoliosis, Anti-NMDA receptor encephalitis, Takayasu arteritis, Hepatic echinococcosis, Lymphangioleiomyomatosis, Amyotrophic lateral sclerosis, Spinal muscular atrophy, Fabry disease, Pompe disease, Duchenne muscular dystrophy, Behçet disease, Alport syndrome, IgA nephropathy, Gaucher disease, Niemann–Pick disease type C, Osteogenesis imperfecta, Primary biliary cholangitis, Primary sclerosing cholangitis, Congenital diaphragmatic hernia, Hirschsprung disease, Inherited epidermolysis bullosa, Hereditary angioedema, Familial adenomatous polyposis, Leber hereditary optic neuropathy, Majeed syndrome, NGLY1 deficiency, ISG15 deficiency.
Cancer
Lung cancer
肺癌Led 80 of the 23,356 English-language PubMed papers on lung cancer with an author in mainland China, 2021–2025: 0.3%.
20 hospitals in Beijing for lung cancer251 hospitals in China for lung cancer
Open trials with this hospital 29
Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 18 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.
- RecruitingA Prospective, Single-arm, Phase II Clinical Trial to Evaluate the Efficacy and Safety of Tafolecimab and Sintilimab Combined With Chemotherapy in Patients With Advanced or Metastatic Driver Gene-negative Non-small Cell Lung Cancer After Failure of First-line Immunotherapy.
- Phase
- Phase 2
- Started
- 2024-05
- Posted
- Registry
- NCT06421298
Age 18 years to 75 years (registered criteria)
Led by Beijing Chest HospitalBeijing
- RecruitingAdebrelimab Plus Chemo and Recaticimab in Perioperative Treatment of Resectable NSCLC
- Phase
- Phase 2
- Started
- 2024-08
- Posted
- Registry
- NCT06467617
Age 18 years to 75 years (registered criteria)
Led by Beijing Chest HospitalBeijing
- RecruitingBeamion LUNG-3: Adjuvant Zongertinib vs Standard Treatment in People With Completely Resected Stage II-IIIB NSCLC Harboring Activating HER2 TKD Mutations
- Phase
- Phase 3
- Started
- 2026-01
- Posted
- Registry
- NCT07195695
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 26 listed hospitals as study sitesBeijing, Changchun, Changsha, Chengdu, Guangzhou, Hangzhou, Harbin, Jinan, Linyi, Nanchang, Nanjing, Shanghai, Shijiazhuang, Suzhou, Taizhou, Tianjin, Wuhan, Xuzhou, Yangzhou, Zhengzhou
- RecruitingSymbiotic-Lung-01 : A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer
- Phase
- Phase 3
- Started
- 2026-01
- Posted
- Registry
- NCT07222566
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 36 listed hospitals as study sitesBeijing, Changchun, Changsha, Chengdu, Chongqing, Fuzhou, Guangzhou, Hangzhou, Hefei, Jiangmen, Jinan, Linyi, Luoyang, Nanchang, Nanjing, Nanning, Shanghai, Taiyuan, Taizhou, Wenzhou, Wuhan, Xiangyang, Xinxiang, Yangzhou, Zhengzhou
- RecruitingDAREON ® -Lung-1: A Study in People With Advanced Small Cell Lung Cancer to Compare Obrixtamig Plus Atezolizumab, Carboplatin, and Etoposide Treatment With Standard Chemoimmunotherapy
- Phase
- Phase 3
- Started
- 2026-04
- Posted
- Registry
- NCT07472517
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 31 listed hospitals as study sitesBeijing, Bengbu, Changsha, Chengdu, Fuzhou, Guangzhou, Hangzhou, Harbin, Jinan, Linyi, Nanchang, Nanjing, Nanning, Ningbo, Shanghai, Taiyuan, Tianjin, Wenzhou, Wuhan, Xiangyang, Xuzhou, Yangzhou, Zhengzhou
- RecruitingA Study of DS-3939a in Participants With Solid Tumors
- Phase
- Phase 1/Phase 2
- Started
- 2026-10
- Posted
- Registry
- NCT07739966
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 13 listed hospitals as study sitesBeijing, Changchun, Changsha, Guangzhou, Hangzhou, Harbin, Jinan, Shanghai, Taizhou, Tianjin, Wuhan, Zhengzhou
- RecruitingSafety, Efficacy, and Pharmacokinetics of BNT327 in Combination With Chemotherapy and Other Investigational Agents for Lung Cancer (ROSETTA Lung-02)
- Phase
- Phase 2/Phase 3
- Started
- 2025-01
- Posted
- Registry
- NCT06712316
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 20 listed hospitals as study sitesBeijing, Bengbu, Changchun, Changsha, Chongqing, Hangzhou, Jinan, Shanghai, Shantou, Shijiazhuang, Suzhou, Taizhou, Wuhan, Yangzhou
- RecruitingSafety and Efficacy of BNT327, an Investigational Therapy in Combination With Chemotherapy for Patients With Untreated Small-cell Lung Cancer
- Phase
- Phase 3
- Started
- 2025-02
- Posted
- Registry
- NCT06712355
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 29 listed hospitals as study sitesBeijing, Bengbu, Changchun, Chongqing, Fuzhou, Guangzhou, Hangzhou, Harbin, Hefei, Jinan, Linyi, Nanchang, Shanghai, Shantou, Shijiazhuang, Suzhou, Taiyuan, Taizhou, Wenzhou, Wuhan, Xiangyang, Xinxiang, Yangzhou, Zhengzhou
- RecruitingThis is a Study to Learn About How the Combination of the Study Medicines Sigvotatug Vedotin Plus Pembrolizumab Works in People With Non-small Cell Lung Cancer With High Levels of PD-L1.
- Phase
- Phase 3
- Started
- 2025-07
- Posted
- Registry
- NCT06758401
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 28 listed hospitals as study sitesBeijing, Changsha, Changzhou, Chengdu, Fuzhou, Guangzhou, Hangzhou, Harbin, Hefei, Jinan, Linyi, Luoyang, Nanchang, Nanjing, Nanning, Shanghai, Taizhou, Tianjin, Wenzhou, Wuhan, Xi'an, Xuzhou, Zhengzhou
- RecruitingClinical Effectiveness and Safety of Trastuzumab Deruxtecan (T-DXd) in Chinese Patients With HER2m NSCLC (RERUN)
- Phase
- Not given
- Started
- 2025-02
- Posted
- Registry
- NCT06809764
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 30 listed hospitals as study sitesBeijing, Fuzhou, Guangzhou, Hangzhou, Hefei, Jinan, Nanchang, Nanjing, Nanning, Nantong, Qingdao, Shanghai, Shenyang, Shenzhen, Shijiazhuang, Wuhan, Xiamen, Zhengzhou
- RecruitingA Study of Navlimetostat (BMS-986504) Alone or in Combination With Izalontamab Brengitecan in Participants With Pre-treated Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC) With Homozygous MTAP Deletion or MTAP Loss (MountainTAP-9)
- Phase
- Phase 2
- Started
- 2025-09
- Posted
- Registry
- NCT06855771
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 8 listed hospitals as study sitesBeijing, Hangzhou, Jinan, Linyi, Nanchang, Nanning, Taizhou, Xiamen
- RecruitingA Study of Adagrasib Plus Pembrolizumab Plus Chemotherapy vs. Placebo Plus Pembrolizumab Plus Chemotherapy in Participants With Previously Untreated Non-squamous Non-small Cell Lung Cancer With KRAS G12C Mutation (KRYSTAL-4)
- Phase
- Phase 3
- Started
- 2025-04
- Posted
- Registry
- NCT06875310
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 39 listed hospitals as study sitesBeijing, Bengbu, Changchun, Changsha, Chengdu, Chongqing, Fuzhou, Guangzhou, Hangzhou, Harbin, Hefei, Jinan, Linyi, Nanchang, Nanjing, Nanning, Shanghai, Shantou, Shenyang, Shenzhen, Shijiazhuang, Suzhou, Taiyuan, Taizhou, Tianjin, Wuhan, Xiamen, Xinxiang, Yangzhou
- RecruitingA Phase Ⅱ Study of RC108 in Combination With Furmonertinib for the First-line Treatment of EGFR-Mutated Combined MET-Positive Unresectable Locally Advanced or Recurrent Metastatic NSCLC
- Phase
- Phase 2
- Started
- 2025-06
- Posted
- Registry
- NCT06962865
Age 18 years to 75 years (registered criteria)
Lead sponsor is not a listed hospital; 23 listed hospitals as study sitesBeijing, Changchun, Changsha, Chengdu, Chongqing, Fuzhou, Guangzhou, Guilin, Hangzhou, Harbin, Jinan, Kunming, Linyi, Shijiazhuang, Taiyuan, Tianjin, Wenzhou, Wuhan, Xiangyang, Yantai, Zhengzhou
- RecruitingA Study of AK112 as Consolidation Treatment for Patients With Limited Stage Small-cell Lung Cancer Who Have Not Progressed Following Concurrent Chemoradiation Therapy
- Phase
- Phase 3
- Started
- 2025-06
- Posted
- Registry
- NCT07010263
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 35 listed hospitals as study sitesAnyang, Beijing, Changchun, Changsha, Chongqing, Fuzhou, Guangzhou, Harbin, Jiangmen, Jinan, Linyi, Nanchang, Nanjing, Nanning, Shanghai, Shenyang, Shijiazhuang, Taiyuan, Tianjin, Wenzhou, Wuhan, Xi'an, Xinxiang, Yinchuan, Zhengzhou, Zunyi
- RecruitingStudy of Oral EGFR Inhibitor DZD6008 Combined With Sunvozertinib in Patients Who Have Advanced NSCLC With EGFR Mutations (TIAN-SHAN8)
- Phase
- Phase 1/Phase 2
- Started
- 2025-07
- Posted
- Registry
- NCT07079475
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 11 listed hospitals as study sitesBeijing, Changsha, Chengdu, Guangzhou, Hangzhou, Jinan, Nanjing, Shanghai, Shenyang, Tianjin
- RecruitingPhase Ib/II Study of Vebreltinib With Furmonertinib in NSCLC Patients With c-Met Amplification After EGFR-TKI Failure
- Phase
- Phase 1/Phase 2
- Started
- 2025-04
- Posted
- Registry
- NCT07087223
Age 18 years to Not stated (registered criteria)
Led by Peking University Cancer Hospital; 7 listed hospitals as study sitesBeijing, Dalian, Shijiazhuang, Tianjin
- RecruitingA Phase 3 Study of Sunvozertinib Versus Placebo as Adjuvant Therapy in Patients With Early-Stage Non-Small Cell Lung Cancer Harboring EGFR Exon 20 Insertion Mutations or PACC Mutations After Radical Surgery
- Phase
- Phase 3
- Started
- 2025-12
- Posted
- Registry
- NCT07182682
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 47 listed hospitals as study sitesBeijing, Changchun, Changsha, Chengdu, Fuzhou, Guangzhou, Hangzhou, Harbin, Hefei, Jinan, Kunming, Nanjing, Nanning, Shanghai, Shenyang, Taiyuan, Taizhou, Tianjin, Wuhan, Xi'an, Xuzhou, Zhengzhou
- RecruitingStudy to Evaluate Efficacy and Safety of Firmonertinib Compared With Investigator's Choice of EGFR Inhibitor as First-Line Treatment in Participants Who Have Locally Advanced or Metastatic NSCLC With EGFR P-Loop and Alpha C-Helix Compressing (PACC) Uncommon Mutations
- Phase
- Phase 3
- Started
- 2025-12
- Posted
- Registry
- NCT07185997
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 45 listed hospitals as study sitesBeijing, Changsha, Chengdu, Chongqing, Dalian, Foshan, Fuzhou, Guangzhou, Hangzhou, Harbin, Hefei, Hohhot, Jinan, Kunming, Linyi, Luoyang, Nanchang, Nanjing, Nanning, Nantong, Qingdao, Shanghai, Shantou, Shenyang, Shijiazhuang, Taiyuan, Tianjin, Weifang, Wuhan, Xinxiang, Zhengzhou
- RecruitingA Study of Ifinatamab Deruxtecan Versus Treatment of Physician's Choice in Subjects With Relapsed Small Cell Lung Cancer
- Phase
- Phase 3
- Started
- 2024-05
- Posted
- Registry
- NCT06203210
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 23 listed hospitals as study sitesBeijing, Changsha, Chengdu, Chongqing, Hangzhou, Harbin, Jinan, Linyi, Nanchang, Shanghai, Shenyang, Tianjin, Urumqi, Wuhan, Xiangyang, Yantai, Zhengzhou
- RecruitingD-1553 Tablet Versus Docetaxel Injection for KRAS G12C Mutation-positive Locally Advanced or Metastatic Non-small Cell Lung Cancer After Prior Standard Therapy Failure
- Phase
- Phase 3
- Started
- 2024-03
- Posted
- Registry
- NCT06300177
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 63 listed hospitals as study sitesAnyang, Beijing, Changchun, Changsha, Changzhou, Chengdu, Chongqing, Fuzhou, Guangzhou, Guilin, Haikou, Hangzhou, Harbin, Hefei, Jinan, Kunming, Lanzhou, Luoyang, Nanchang, Nanjing, Nanning, Nantong, Shanghai, Shenyang, Shijiazhuang, Taiyuan, Tianjin, Urumqi, Weifang, Wenzhou, Wuhan, Wuxi, Xi'an, Xiamen, Xinxiang, Xuzhou, Zhanjiang, Zhengzhou, Zunyi
- RecruitingA Study of Calderasib (MK-1084) Plus Pembrolizumab (MK-3475) in Participants With KRAS G12C Mutant Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥50% (MK-1084-004/KANDLELIT-004)
- Phase
- Phase 3
- Started
- 2024-05
- Posted
- Registry
- NCT06345729
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 36 listed hospitals as study sitesBeijing, Changsha, Chengdu, Chongqing, Fuzhou, Guangzhou, Hangzhou, Harbin, Hefei, Jinan, Linyi, Nanchang, Nanjing, Shanghai, Suzhou, Taiyuan, Taizhou, Urumqi, Wenzhou, Wuhan, Wuxi, Xi'an, Xiamen, Zhengzhou
- RecruitingA Clinical Study of TQB2450 Injection Combined With Chemotherapy or Anlotinib Hydrochloride Capsule in the Treatment of Non Small Cell Lung Cancer
- Phase
- Phase 2
- Started
- 2023-06
- Posted
- Registry
- NCT05913089
Age 18 years to 80 years (registered criteria)
Lead sponsor is not a listed hospital; 9 listed hospitals as study sitesBeijing, Fuzhou, Shanghai, Taiyuan, Tianjin, Weifang
- RecruitingA Study Evaluating Sotorasib Platinum Doublet Combination Versus Pembrolizumab Platinum Doublet Combination as a Front-Line Therapy in Participants With Stage IV or Advanced Stage IIIB/C Nonsquamous Non-Small Cell Lung Cancers (CodeBreaK 202)
- Phase
- Phase 3
- Started
- 2023-11
- Posted
- Registry
- NCT05920356
Age 18 years to 100 years (registered criteria)
Lead sponsor is not a listed hospital; 45 listed hospitals as study sitesAnyang, Beijing, Bengbu, Changchun, Changsha, Chengdu, Chongqing, Fuzhou, Guangzhou, Hangzhou, Harbin, Hefei, Jinan, Kunming, Linyi, Luoyang, Nanchang, Nanjing, Nanning, Nantong, Shanghai, Shantou, Shijiazhuang, Taiyuan, Taizhou, Tianjin, Weifang, Wuhan, Xi'an, Xiamen, Xiangyang, Zhengzhou
- RecruitingA Study to Evaluate the Efficacy and Safety of Sutetinib Maleate Capsule in Locally Advanced or Metastatic NSCLC
- Phase
- Phase 2
- Started
- 2023-12
- Posted
- Registry
- NCT06010329
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 13 listed hospitals as study sitesBeijing, Chengdu, Guangzhou, Hangzhou, Harbin, Jinan, Nanchang, Nanjing, Shanghai, Wuhan, Zhengzhou
- RecruitingA Study to Assess Disease Activity and Adverse Events of Intravenous (IV) Telisotuzumab Vedotin Compared to IV Docetaxel in Adult Participants With Previously Treated Non-Squamous Non-Small Cell Lung Cancer (NSCLC)
- Phase
- Phase 3
- Started
- 2022-03
- Posted
- Registry
- NCT04928846
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 41 listed hospitals as study sitesBeijing, Changchun, Changsha, Chengdu, Chongqing, Dalian, Fuzhou, Guangzhou, Hangzhou, Harbin, Hefei, Hohhot, Jinan, Kunming, Linyi, Nanchang, Nanjing, Nanning, Nantong, Shanghai, Shantou, Shenyang, Shijiazhuang, Taiyuan, Taizhou, Tianjin, Urumqi, Wuhan, Xi'an, Xiamen, Zhanjiang, Zhengzhou
- RecruitingStudy to Evaluate Sutetinib Maleate Capsule in Locally Advanced or Metastatic Non-small Cell Lung Cancer
- Phase
- Phase 2
- Started
- 2022-09
- Posted
- Registry
- NCT05168566
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 19 listed hospitals as study sitesBeijing, Bengbu, Changchun, Changsha, Chengdu, Guangzhou, Hangzhou, Harbin, Linyi, Nanjing, Shanghai, Shenyang, Wuhan, Zhengzhou
- RecruitingPhase 1/2a Study of JAB-21822 Plus JAB-3312 in Patients With Advanced Solid Tumors Harboring KRAS p.G12C Mutation
- Phase
- Phase 1/Phase 2
- Started
- 2022-04
- Posted
- Registry
- NCT05288205
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 24 listed hospitals as study sitesBeijing, Changsha, Fuzhou, Guangzhou, Harbin, Hefei, Hohhot, Jinan, Linyi, Shanghai, Shenyang, Shenzhen, Wuhan, Xiamen, Zhengzhou
- Not yet recruitingStudy of MCLA-129 in the Treatment of Advanced Non-small Cell Lung Cancer with AGA and MET Amplification.
- Phase
- Phase 2
- Started
- 2025-03
- Posted
- Registry
- NCT06885840
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 17 listed hospitals as study sitesBeijing, Changchun, Changsha, Foshan, Guangzhou, Hangzhou, Harbin, Hefei, Jinan, Lanzhou, Shenyang, Tianjin, Wuhan, Xi'an, Zhengzhou
- Not yet recruitingYK-029A as First-Line Treatment Versus Platinum-Based Chemotherapy for Non-Small Cell Lung Cancer (NSCLC) With EGFR Exon 20 Insertion Mutations
- Phase
- Phase 3
- Started
- 2023-05
- Posted
- Registry
- NCT05767892
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 41 listed hospitals as study sitesBeijing, Bengbu, Changsha, Chengdu, Chongqing, Fuzhou, Guangzhou, Hangzhou, Harbin, Hefei, Hohhot, Jinan, Kunming, Luoyang, Nanchang, Nanjing, Qingdao, Shanghai, Shenyang, Shijiazhuang, Suzhou, Taiyuan, Taizhou, Tianjin, Wuhan, Xi'an, Xiamen, Zhengzhou
Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.
The records behind these numbers
Hospital name read automatically from author addresses, not yet checked by hand.
Papers it led80
- Superior Performance of Synchronized Percutaneous Microwave Ablation and Immediate Percutaneous Biopsy for Highly Suspected Malignant Pulmonary Ground-Glass Nodules.
- Global patterns and trends in mesothelioma incidence: A retrospective cross-sectional study.
- Multi-omics data-based modeling reveals tumorigenesis- and prognosis-associated genes with clinical potential in lung adenocarcinoma.
- Clinical and imaging features of co-existent pulmonary tuberculosis and lung cancer: a population-based matching study in China.
- Prognostic Value of Surgical Resection for Non-small-cell Lung Cancer Patients Comorbid With Minimal Pleural Effusion.
- Is adjuvant immunotherapy necessary after neoadjuvant chemoimmunotherapy in patients with resectable stage III NSCLC? A two-center real-world study.
- Whole Exome Sequencing Study Identifies Distinct Characteristics of Transformed Small Cell Lung Cancer With EGFR Mutation Compared to De Novo Small Cell and Primary Non-Small Cell Lung Cancers.
- Evaluation of cfDNA fragmentation characteristics in plasma for the diagnosis of lung cancer: A prospective cohort study.
- Effect of neoadjuvant targeted therapy on the tumor microenvironment in resectable lung adenocarcinoma.
- Two inflammation-related genes model could predict risk in prognosis of patients with lung adenocarcinoma.
- Impact of air pollution on the progress-free survival of non-small cell lung cancer patients with anti-PD-1/PD-L1 immunotherapy: A cohort study.
- Dose-dependent efficacy of CX1003 in NSCLC immunotherapy: High dose for T cell response, low dose for apoptosis.
- Combined detection of SHOX2 and PTGER4 methylation with serum marker CYFRA21-1 for improved diagnosis of malignant pleural mesothelioma.
- Multimodal prediction of tyrosine kinase inhibitors therapy outcomes in advanced EGFR-mutated NSCLC patients.
- Liquid biopsy using plasma proteomics in predicting efficacy and tolerance of PD-1/PD-L1 blockades in NSCLC: a prospective exploratory study.
- CD8+ TILs in necrotic tumors after neoadjuvant immunochemotherapy predict outcomes in non-small-cell lung cancer patients.
- A cohort study of circulating biomarkers to predict the efficacy and prognosis of immune combination therapy in non-small-cell lung cancer.
- Peripheral Immune Cell Profiles as Predictive Biomarkers of Immune Checkpoint Inhibitor Efficacy in Elderly Patients With Advanced Non-Small Cell Lung Cancer.
- Predictive Value of the Estimated Dose of Radiation to Immune Cells Versus Conventional Parameters in Elderly Patients With Unresectable Stage III NSCLC: A Two-Center Real-World Study.
- Chinese Expert Consensus on Leptomeningeal Metastases of Lung Cancer.
- SARS-CoV-2 Infection Alters the Immune Microenvironment in Lung Cancer Patients Undergoing Immunotherapy and Affects Treatment Outcomes.
- The characteristics and prognoses of 72 postoperative synchronous multiple primary lung cancer patients.
- The Biological Role of Macrophage in Lung and Its Implications in Lung Cancer Immunotherapy.
- Identification of JUN gene and cellular microenvironment in response to PD-1 blockade treatment in lung cancer patients via single-cell RNA sequencing.
- Artificial intelligence-driven computer aided diagnosis system provides similar diagnosis value compared with doctors' evaluation in lung cancer screening.
- Integration of clinical and blood parameters in risk prognostication for patients receiving immunochemotherapy for extensive stage small cell lung cancer: real-world data from two centers.
- Value of preoperative evaluation of FEV1 in patients with destroyed lung undergoing pneumonectomy - a 20-year real-world study.
- A case of squamous cell carcinoma of the lung misdiagnosed as tuberculosis. Is HPV infected by oral sex the causative agent?
- Increased Incidence of Severe Adverse Events in Non-Small Cell Lung Cancer Patients with Previous Tuberculosis Episode Treated with PD-1 Inhibitors.
- T-cell subsets and cytokines are indicative of neoadjuvant chemoimmunotherapy responses in NSCLC.
- The Ribonuclease ZC3H12A is required for self-inflicted DNA breaks after DNA damage in small cell lung cancer cells.
- Pan-cancer analysis predicts CANT1 as a potential prognostic, immunologic biomarker.
- A deep learning model integrating multisequence MRI to predict EGFR mutation subtype in brain metastases from non-small cell lung cancer.
- A case of neoadjuvant targeted therapy with pralsetinib for locally advanced lung adenocarcinoma with RET fusion mutation.
- The prognostic significance of lymph nodes in patients with pT1c33N0M0 non-small cell lung cancer: a retrospective study.
- Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Is Associated With Recurrence and Survival of Resectable Non-Small Cell Lung Cancer (NSCLC): A Retrospective Study.
- Predicting EGFR T790M Mutation in Brain Metastases Using Multisequence MRI-Based Radiomics Signature.
- Plasma hepatocyte growth factor as a noninvasive biomarker in small cell lung cancer.
- Post-therapeutic circulating tumor cell-associated white blood cell clusters predict poor survival in patients with advanced driver gene-negative non-small cell lung cancer.
- Mutation status analysis of 58 patients with advanced ALK fusion gene positive non small cell lung cancer.
- Chemotherapy for advanced pulmonary sarcomatoid carcinoma: a population-based propensity score matching study.
- High accuracy epidermal growth factor receptor mutation prediction via histopathological deep learning.
- Deep learning-based diagnosis of histopathological patterns for invasive non-mucinous lung adenocarcinoma using semantic segmentation.
- Longitudinal detection of subcategorized CD44v6+ CTCs and circulating tumor endothelial cells (CTECs) enables novel clinical stratification and improves prognostic prediction of small cell lung cancer: A prospective, multi-center study.
- Real-world analysis of the prognostic value of EGFR mutation detection in plasma ctDNA from patients with advanced non-small cell lung cancer.
- CT-based nomogram for early identification of T790M resistance in metastatic non-small cell lung cancer before first-line epidermal growth factor receptor-tyrosine kinase inhibitors therapy.
- Research progress of extracellular vesicles as biomarkers in immunotherapy for non-small cell lung cancer.
- Immunotherapy efficacy predictive tool for lung adenocarcinoma based on neural network.
- PCSK9 regulates the efficacy of immune checkpoint therapy in lung cancer.
- Acquired resistance to EGFR-TKIs in NSCLC mediates epigenetic downregulation of MUC17 by facilitating NF-κB activity via UHRF1/DNMT1 complex.
- Two germline mutations can serve as genetic susceptibility screening makers for a lung adenocarcinoma family.
- The artificial intelligence and machine learning in lung cancer immunotherapy.
- Genetic profiling of circulating cell-free DNA from cerebrospinal fluid and paired plasma in ALK-positive lung cancer with brain metastases.
- ASO Author Reflections: A Simple Method to Predict Risk Factors of Complications After Pneumonectomy.
- A Multiple-Center Nomogram to Predict Pneumonectomy Complication Risk for Non-Small Cell Lung Cancer Patients.
- A single center analysis of first-line treatment in advanced KRAS mutant non-small cell lung cancer: real-world practice.
- Identification of serum MiRNAs as candidate biomarkers for non-small cell lung cancer diagnosis.
- Expression and potential role of CCL4 in CD8+T cells in NSCLC.
- Circulating myeloid-derived suppressors cells correlate with clinicopathological characteristics and outcomes undergoing neoadjuvant chemoimmunotherapy in non-small cell lung cancer.
- CD155 expression impairs anti-PD1 therapy response in non-small cell lung cancer.
- IncRNA Linc00511 Upregulation Elevates TGFBR1 and Participates in the Postoperative Distant Recurrence of Non-Small-Cell Lung Cancer by Targeting miR-98-5p.
- Concomitant novel ALK-SSH2, EML4-ALK and ARID2-ALK, EML4-ALK double-fusion variants and confer sensitivity to crizotinib in two lung adenocarcinoma patients, respectively.
- Differentiating EGFR from ALK mutation status using radiomics signature based on MR sequences of brain metastasis.
- CD137 Agonists Targeting CD137-Mediated Negative Regulation Show Enhanced Antitumor Efficacy in Lung Cancer.
- Combined application of bevacizumab and PD-1 blockade displays durable treatment effects by increasing the infiltration and cytotoxic function of CD8+ T cells in lung cancer.
- Pathological complete response to neoadjuvant chemoimmunotherapy correlates with peripheral blood immune cell subsets and metastatic status of mediastinal lymph nodes (N2 lymph nodes) in non-small cell lung cancer.
- Targeting brain lesions of non-small cell lung cancer by enhancing CCL2-mediated CAR-T cell migration.
- Long non-coding RNA BZRAP1-AS1 functions in malignancy and prognosis for non-small-cell lung cancer.
- IGFBP7 overexpression promotes acquired resistance to AZD9291 in non-small cell lung cancer.
- Identification of a competing endogenous RNA axis "SVIL-AS1/miR-103a/ICE1" associated with chemoresistance in lung adenocarcinoma by comprehensive bioinformatics analysis.
- Multigene PCR using both cfDNA and cfRNA in the supernatant of pleural effusion achieves accurate and rapid detection of mutations and fusions of driver genes in patients with advanced NSCLC.
- Engineering of hybrid anticancer drug-loaded polymeric nanoparticles delivery system for the treatment and care of lung cancer therapy.
- Associated factors of co-existent pulmonary tuberculosis and lung cancer: A case-control study.
- Hyaluronic Acid Correlates With Bone Metastasis and Predicts Poor Prognosis in Small-Cell Lung Cancer Patients.
- Profiling of DNA damage and repair pathways in small cell lung cancer reveals a suppressive role in the immune landscape.
- Role of aneuploid circulating tumor cells and CD31+ circulating tumor endothelial cells in predicting and monitoring anti-angiogenic therapy efficacy in advanced NSCLC.
- Heterogeneity and prognosis of programmed cell death-ligand 1 expression in the circulating tumor cells of non-small cell lung cancer.
- Differential MUC22 expression by epigenetic alterations in human lung squamous cell carcinoma and adenocarcinoma.
- A Modified Method to Isolate Circulating Tumor Cells and Identify by a Panel of Gene Mutations in Lung Cancer.
- ALK-rearranged squamous cell carcinoma of the lung.
Chinese-language papers (not in the count)18
- [Analysis of the Correlation between Immune Cell Subsets in Bronchoalveolar Lavage Fluid and the Efficacy of First-line Use of Immunotherapy in Advanced Non-small Cell Lung Cancer: A Case-control Study].
- [Clinicopathological Characteristics and Prognosis Analysis of 39 Patients with Pulmonary Sarcomatoid Carcinoma].
- [Clinical characteristics and prognostic factors of epidermal growth factor receptor-mutated non-small cell lung cancer transformed into small-cell lung cancer after treatment].
- [Aprospective study of detection and clinical significance of bone marrow tumor cells in small cell lung cancer].
- [Research Progresses in the Treatment of NSCLC with MET Gene Variants: A Riview].
- [Advances in ICIs Therapy after TKIs Resistance in Patients with EGFR Mutant NSCLC: A Review].
- [Analysis of the Efficacy of Immunotherapy in Elderly Patients with Lung Cancer].
- [Research Progress of Immunotherapy Biomarkers for Non-small Cell Lung Cancer].
- [Expression of CD44 in Tumor Tissue and Serum of Small Cell Lung Cancer and Its Clinical Prognostic Significance].
- [Analysis of the Efficacy of Immunotherapy on the Posterior Lines of Advanced EGFR Mutant Patients with Non-small cell Lung Cancer].
- [Preliminary Efficacy Evaluation of Neoadjuvant Immunotherapy Combined with Chemotherapy in Resectable Non-small Cell Lung Cancer].
- [Research Progress of Single Cell Sequencing in Lung Cancer].
- [CD45RO⁺ Memory T Lymphocytes As A Candidate Marker for Non-small Cell Lung Cancer].
- [Application Progress of Immune Checkpoint Inhibitors in Oncogene-driven Advanced Non-small Cell Lung Cancer].
- [Evaluation of Response to Immune Checkpoint Inhibitor Monotherapy or Combination with Chemotherapy for Patients with Advanced Non-small Cell Lung Cancer and High PD-L1 Expression].
- [Ongoing Evaluation of Immune-related Response Assessment in Brain Metastases].
- [Developments in Immunotherapy for Advanced Non-small Cell Lung Cancer].
- [A Real-world Study on the Assessment of Pathological Characteristics and Targeted Therapeutic Effect of Non-small Cell Lung Cancer Patients with Positive Driving Genes and High PD-L1 Expression].
All its trials on ClinicalTrials.gov, any status96
- Adebrelimab Plus Chemo and Recaticimab in Perioperative Treatment of Resectable NSCLC
- The Efficacy and Drug Resistance Molecular Biology of Apatinib Combined With EGFR-TK1 Treated for Advanced Slow-progressed Non-Small Cell Lung Cancer (NSCLC)
- Endostar Durative Transfusion Combining With Gemcitabine-Cisplatin to Treat Non-Small Cell Lung Cancer (NSCLC)
- A Prospective, Single-arm, Phase II Clinical Trial to Evaluate the Efficacy and Safety of Tafolecimab and Sintilimab Combined With Chemotherapy in Patients With Advanced or Metastatic Driver Gene-negative Non-small Cell Lung Cancer After Failure of First-line Immunotherapy.
- A Study of DS-3939a in Participants With Solid Tumors
- DAREON ® -Lung-1: A Study in People With Advanced Small Cell Lung Cancer to Compare Obrixtamig Plus Atezolizumab, Carboplatin, and Etoposide Treatment With Standard Chemoimmunotherapy
- Symbiotic-Lung-01 : A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer
- Beamion LUNG-3: Adjuvant Zongertinib vs Standard Treatment in People With Completely Resected Stage II-IIIB NSCLC Harboring Activating HER2 TKD Mutations
- A Phase Ⅱ Study of RC108 in Combination With Furmonertinib for the First-line Treatment of EGFR-Mutated Combined MET-Positive Unresectable Locally Advanced or Recurrent Metastatic NSCLC
- Study of MCLA-129 in the Treatment of Advanced Non-small Cell Lung Cancer with AGA and MET Amplification.
- Phase Ib/II Study of Vebreltinib With Furmonertinib in NSCLC Patients With c-Met Amplification After EGFR-TKI Failure
- A Study of Adagrasib Plus Pembrolizumab Plus Chemotherapy vs. Placebo Plus Pembrolizumab Plus Chemotherapy in Participants With Previously Untreated Non-squamous Non-small Cell Lung Cancer With KRAS G12C Mutation (KRYSTAL-4)
- This is a Study to Learn About How the Combination of the Study Medicines Sigvotatug Vedotin Plus Pembrolizumab Works in People With Non-small Cell Lung Cancer With High Levels of PD-L1.
- Study to Evaluate Efficacy and Safety of Firmonertinib Compared With Investigator's Choice of EGFR Inhibitor as First-Line Treatment in Participants Who Have Locally Advanced or Metastatic NSCLC With EGFR P-Loop and Alpha C-Helix Compressing (PACC) Uncommon Mutations
- A Phase 3 Study of Sunvozertinib Versus Placebo as Adjuvant Therapy in Patients With Early-Stage Non-Small Cell Lung Cancer Harboring EGFR Exon 20 Insertion Mutations or PACC Mutations After Radical Surgery
- Safety and Efficacy of BNT327, an Investigational Therapy in Combination With Chemotherapy for Patients With Untreated Small-cell Lung Cancer
- Study of Oral EGFR Inhibitor DZD6008 Combined With Sunvozertinib in Patients Who Have Advanced NSCLC With EGFR Mutations (TIAN-SHAN8)
- Safety, Efficacy, and Pharmacokinetics of BNT327 in Combination With Chemotherapy and Other Investigational Agents for Lung Cancer (ROSETTA Lung-02)
- A Study of Navlimetostat (BMS-986504) Alone or in Combination With Izalontamab Brengitecan in Participants With Pre-treated Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC) With Homozygous MTAP Deletion or MTAP Loss (MountainTAP-9)
- Clinical Effectiveness and Safety of Trastuzumab Deruxtecan (T-DXd) in Chinese Patients With HER2m NSCLC (RERUN)
- A Study of AK112 as Consolidation Treatment for Patients With Limited Stage Small-cell Lung Cancer Who Have Not Progressed Following Concurrent Chemoradiation Therapy
- A Study of Ifinatamab Deruxtecan Versus Treatment of Physician's Choice in Subjects With Relapsed Small Cell Lung Cancer
- A Study of Calderasib (MK-1084) Plus Pembrolizumab (MK-3475) in Participants With KRAS G12C Mutant Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥50% (MK-1084-004/KANDLELIT-004)
- D-1553 Tablet Versus Docetaxel Injection for KRAS G12C Mutation-positive Locally Advanced or Metastatic Non-small Cell Lung Cancer After Prior Standard Therapy Failure
- A Study Evaluating Sotorasib Platinum Doublet Combination Versus Pembrolizumab Platinum Doublet Combination as a Front-Line Therapy in Participants With Stage IV or Advanced Stage IIIB/C Nonsquamous Non-Small Cell Lung Cancers (CodeBreaK 202)
- A Study to Evaluate the Efficacy and Safety of Sutetinib Maleate Capsule in Locally Advanced or Metastatic NSCLC
- YK-029A as First-Line Treatment Versus Platinum-Based Chemotherapy for Non-Small Cell Lung Cancer (NSCLC) With EGFR Exon 20 Insertion Mutations
- A Clinical Study of TQB2450 Injection Combined With Chemotherapy or Anlotinib Hydrochloride Capsule in the Treatment of Non Small Cell Lung Cancer
- A Study to Assess Disease Activity and Adverse Events of Intravenous (IV) Telisotuzumab Vedotin Compared to IV Docetaxel in Adult Participants With Previously Treated Non-Squamous Non-Small Cell Lung Cancer (NSCLC)
- Phase 1/2a Study of JAB-21822 Plus JAB-3312 in Patients With Advanced Solid Tumors Harboring KRAS p.G12C Mutation
- Study to Evaluate Sutetinib Maleate Capsule in Locally Advanced or Metastatic Non-small Cell Lung Cancer
- A Phase I Clinical Study to Evaluate the PK Profile, Efficacy, Safety and Immunogenicity of HLX17 vs. Keytruda® in Multiple Resected Solid Tumors
- A Study of ES102 in Combination With Toripalimab in Subjects With Advanced Non-small Cell Lung Cancer
- Evaluating the Preliminary Efficacy and Safety of JS207 in NSCLC After Progression Following Platinum-based Chemotherapy and Immunotherapy
- A Study to Compare Uliledlimab Combined With Sintilimab and Chemotherapy Versus Sintilimab Combined With Chemotherapy in Patients With Previously Untreated Locally Advanced Unresectable or Metastatic Non-small Cell Lung Cancer
- A Clinical Study of TQB2450 Combined With Anlotinib in Limited-Stage Small Cell Lung Cancer Patients
- A Study of SGN-B6A Versus Docetaxel in Previously Treated Non-small Cell Lung Cancer
- A Phase 2 Study of Anvumetostat in Participants With MTAP-deleted Advanced NSCLC (MTAPESTRY 201)
- A Study to Compare Uliledlimab Combined With Toripalimab, Toripalimab Monotherapy, and Pembrolizumab Monotherapy in Patients With Previously Untreated Locally Advanced Unresectable or Metastatic PD-L1- and CD73- Selected Non-Small Cell Lung Cancer
- Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients
- A Study of Participants in China With Non-Small-Cell Lung Cancer That is Unable to be Treated With Surgery
- TQB2450 Injection Combined With Chemotherapy Followed by Sequential Combination With Anlotinib Hydrochloride Capsule for First-line Treatment of Advanced Squamous Non-small Cell Lung Cancer.
- A Study of Subcutaneous (SC) Pembrolizumab Coformulated With Berahyaluronidase Alfa (MK-3475A) vs Intravenous Pembrolizumab in Adult Participants With Metastatic Non-small Cell Lung Cancer (NSCLC) (MK-3475A-D77)
- Study of Pembrolizumab (MK-3475) Monotherapy Versus Sacituzumab Govitecan in Combination With Pembrolizumab for Participants With Metastatic Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥50% (MK-3475-D46)
- Study Comparing Tarlatamab With Standard of Care Chemotherapy in Relapsed Small Cell Lung Cancer
- A Study of T3011 Administered Via Intravenously in Patients With Advanced Solid Tumors.
- A Study of DZD9008 Versus Platinum-Based Doublet Chemotherapy in Local Advanced or Metastatic Non-small Cell Lung Cancer (WU-KONG28)
- A Trial of Camrelizumab Combined With Famitinib Malate in Treatment Naïve Subjects With PD-L1-Positive Recurrent or Metastatic Non-Small Cell Lung Cancer
- A Study of Atezolizumab in High PD-L1 Expression, Chemotherapy-Naïve Patients With Stage IV Non-Squamous or Squamous Non-Small Cell Lung Cancer
- Phase II Study Investigating the Combination of Encorafenib and Binimetinib in BRAF V600E Mutated Chinese Patients With Metastatic Non-Small Cell Lung Cancer
- A Clinical Study of TQB2450 Injection Combined With Anlotinib Hydrochloride Capsules Versus K Drug in the Treatment of First-line Non-small Cell Lung Cancer(NSCLC)
- A Study of Ociperlimab With Tislelizumab Compared to Pembrolizumab in Participants With Untreated Lung Cancer
- Lorlatinib Continuation Study
- Coformulation of Pembrolizumab/Vibostolimab (MK-7684A) Versus Pembrolizumab (MK-3475) Monotherapy for Programmed Cell Death 1 Ligand 1 (PD-L1) Positive Metastatic Non-Small Cell Lung Cancer (MK-7684A-003, KEYVIBE-003)
- A Study of Atezolizumab in Combination With Bevacizumab in Patients With EGFR Mutation Positive Stage IIIB-IV Non-Squamous Non-Small Cell Lung Cancer
- Study of Atezolizumab Plus Carboplatin and Etoposide With or Without Tiragolumab in Participants With Untreated Extensive-Stage Small Cell Lung Cancer
- A Study of Atezolizumab and Tiragolumab Compared With Durvalumab in Participants With Locally Advanced, Unresectable Stage III Non-Small Cell Lung Cancer (NSCLC)
- Almonertinib Plus Chemotherapy as First-line Treatment in Patients With EGFR Concomitant Non-EGFR Driver Gene Mutant, Locally Advanced or Metastatic NSCLC
- A Real-world Study of Adjuvant Therapy in Early Stage NSCLC With EGFR Mutation-Positive in China
- Almonertinib Plus Chemotherapy as First-line Treatment in Patients With EGFR Concomitant Tumor Suppressor Gene Mutation
- TAK-788 as First-Line Treatment Versus Platinum-Based Chemotherapy for Non-Small Cell Lung Cancer (NSCLC) With EGFR Exon 20 Insertion Mutations
- A Study of Bevacizumab, Carboplatin, and Paclitaxel or Pemetrexed With or Without Atezolizumab in Chemotherapy-Naïve Patients With Stage IV Non-Squamous Non-Small Cell Lung Cancer (IMpower151)
- Cancer Genome Atlas of China:Lung Cancer
- ASK120067 Versus Gefitinib as First-line Treatment for EGFRm Locally Advanced or Metastatic NSCLC
- A Efficacy and Safety Study of Anlotinib Hydrochloride Capsule Combined With Chemotherapy Versus Placebo Combined With Chemotherapy as First-line Treatment in Subjects With Advanced Non-squamous Cell Non-small Cell Lung Cancer
- A Study of Lorlatinib in ALK Inhibitor-Treated ALK-Positive NSCLC in China
- A Study of Brigatinib Compared to Alectinib in Adults With Non-Small-Cell Lung Cancer
- A Study Evaluates the Safety and Efficacy of WX-0593 in ALK -Positive, or ROS1-positive Non-small Cell Lung Cancer
- Poziotinib in Patients With NSCLC Having EGFR or HER2 Exon 20 Insertion Mutation
- A Study of Tislelizumab in Combination With Chemotherapy Versus Chemotherapy in Advanced Lung Cancer
- The Tracking Molecular Evolution for NSCLC (T-MENC) Study
- A Study of Niraparib as Maintenance Therapy Following First-Line Platinum-Based Chemotherapy in Patients With Extensive Stage Small Cell Lung Cancer
- Anti-PD-1 in Combination With Chemotherapy as First-Line Treatment to Lung Cancer
- Comparison of Efficacy and Safety of Tislelizumab (BGB-A317) Versus Docetaxel as Treatment in the Second- or Third-line Setting in Participants With Non-Small Cell Lung Cancer (NSCLC)
- Safety, Tolerability, Pharmacokinetics and Anti-tumour Activity of ASK120067 in Locally Advanced and Metastatic Non Small Cell Lung Cancer
- A Study of Atezolizumab Compared With Docetaxel in Non-Small Cell Lung Cancer (NSCLC) After Failure With Platinum-Containing Chemotherapy
- A Phase I/II Clinical Study of SAF-189s in Non-small Cell Lung Cancer (NSCLC) Patients
- eXalt3: Study Comparing X-396 (Ensartinib) to Crizotinib in ALK Positive Non-Small Cell Lung Cancer (NSCLC) Patients
- A Study to Evaluate and Compare the Efficacy and Safety of Alectinib Versus Crizotinib and to Evaluate the Pharmacokinetics of Alectinib in Asian Participants With Treatment-Naive Anaplastic Lymphoma Kinase (ALK)-Positive Advanced Non-Small Cell Lung Cancer (NSCLC)
- A Study of TAK-788 in Adults With Non-Small Cell Lung Cancer
- Study of Anlotinib in Patients With Advanced Non-small Cell Lung Cancer(ALTER0303)
- A Phase III Clinical Trial of Fruquintinib in Patients With Advanced Non-small Cell Lung Cancer
- Uniportal Versus Triportal Thoracoscopic Lobectomy and Sublobectomy for Early Stage Lung Cancer
- High Dose Icotinib in Advanced Non-small Cell Lung Cancer With EGFR 21 Exon Mutation
- Icotinib Versus Placebo as Adjuvant Therapy in EGFR-mutant Lung Adenocarcinoma
- A Clinical Trial of Fruquintinib in Patients With Advanced Non-small Cell Lung Cancer
- Phase II Safety and Efficacy Study of Crizotinib in East Asian Patients With ROS1 Positive, ALK Negative Advanced NSCLC
- Tepotinib With Gefitinib in Participants With Locally Advanced or Metastatic NSCLC (INSIGHT)
- Chidamide in Combination With Carboplatin and Paclitaxel in Advanced Non-small Cell Lung Cancer
- A Study Of Crizotinib Versus Chemotherapy In Previously Untreated ALK Positive East Asian Non-Small Cell Lung Cancer Patients
- A Study of Bevacizumab Versus Placebo in Combination With Carboplatin/Paclitaxel in Participants With Advanced or Recurrent Non-Squamous Non-Small Cell Lung Cancer Who Have Not Received Previous Chemotherapy
- Recombinant Endostatin Combined With Vinorelbine and Cisplatin in Patients With Advanced Non-small Cell Lung Cancer
- Icotinib in Advanced Metastatic Patients With NSCLC Previously Treated With Chemotherapy
- BIBW 2992 (Afatinib) vs Gemcitabine-cisplatin in 1st Line Non-small Cell Lung Cancer (NSCLC)
- Safety and Efficacy Study of Icotinb in Non-small Cell Lung Cancer (NSCLC) Patients
- Cancer Vaccine Study for Stage III, Unresectable, Non-small Cell Lung Cancer (NSCLC) in the Asian Population
Cancer
Neuroblastoma
神经母细胞瘤Led 1 of the 1,132 English-language PubMed papers on neuroblastoma with an author in mainland China, 2021–2025: 0.09%.
- Trials led
- 0
- any status, ClinicalTrials.gov
- Open trials led
- 0
- recruiting or about to
- Open trials as a site
- 0
- led by another institution
23 hospitals in Beijing for neuroblastoma321 hospitals in China for neuroblastoma
No open trial on neuroblastoma lists this hospital on ClinicalTrials.gov on 13 Nov 2026.
The records behind these numbers
Hospital name read automatically from author addresses, not yet checked by hand.
Other diseases
Idiopathic pulmonary fibrosis
特发性肺纤维化Led no English-language PubMed papers on idiopathic pulmonary fibrosis in 2021–2025. Its linked research records are below.
- Papers led
- 0
- 2021–2025
- Open trials led
- 0
- recruiting or about to
- Open trials as a site
- 0
- led by another institution
25 hospitals in Beijing for idiopathic pulmonary fibrosis288 hospitals in China for idiopathic pulmonary fibrosis
No open trial on idiopathic pulmonary fibrosis lists this hospital on ClinicalTrials.gov on 13 Nov 2026.
The records behind these numbers
Hospital name read automatically from author addresses, not yet checked by hand.
Chinese-language papers (not in the count)1
All its trials on ClinicalTrials.gov, any status1
Getting in touch
Name card to show staff or a driver
首都医科大学附属北京胸科医院
Beijing Chest Hospital
北京
Large hospitals often have several campuses. Confirm the campus with the hospital before travelling.
Inquiry letter in English and Chinese
Fill in the brackets, then send it through the contact options on the hospital's international office or official website. Nothing typed here leaves this device.
Records hospitals usually ask for
- A recent summary or letter from the treating doctor
- Pathology report
- Scans (CT, MRI, PET) with their reports, and the images if possible
- Treatments so far, with dates
- Current medicines
What to do next
Where these numbers come from
Papers
English-language PubMed papers whose first or last author lists this hospital as their first affiliation, 2021–2025. Definitions
Trials
ClinicalTrials.gov records naming this hospital as lead sponsor or site, as of 8 Nov 2026.
Identifiers and other names
ROR
Beijing Thoracic Tumor and Tuberculosis Hospital; Central Tuberculosis Institute